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ABSTRACT This study aimed to validate a comprehensive diagnostic protocol
based on real-time PCR for the rapid detection and identiﬁcation of Bordetella per-
tussis, Bordetella parapertussis, and Bordetella holmesii, as well as its implementation
in the diagnostic routine of a reference children’s hospital. The new algorithm in-
cluded a triplex quantitative PCR (qPCR) targeting IS481 gene (in B. pertussis, B. hol-
mesii, and some Bordetella bronchiseptica strains), pIS1001 (B. parapertussis-speciﬁc)
and rnase P as the human internal control. Two conﬁrmatory singleplex tests for B.
pertussis (ptxA-Pr) and B. holmesii (hIS1001) were performed if IS481 was positive. An-
alytical validation included determination of linear range, linearity, efﬁciency, preci-
sion, sensitivity, and a reference panel with clinical samples. Once validated, the new
algorithm was prospectively implemented in children with clinical suspicion of
whooping cough presenting to Hospital Sant Joan de Deu (Barcelona, Spain) over
12 months. Lower limits of detection obtained were 4.4, 13.9, and 27.3 genomic
equivalents/ml of sample for IS481 (on B. pertussis), pIS1001 and hIS1001, and 777.9
for ptxA-Pr. qPCR efﬁciencies ranged from 86.0% to 96.9%. Intra- and interassay vari-
abilities were 3% and 5%, respectively. Among 566 samples analyzed, B. pertus-
sis, B. holmesii, and B. parapertussis were detected in 11.1%, 0.9% (only in females
4 years old), and 0.2% of samples, respectively. The new algorithm proved to be a
useful microbiological diagnostic tool for whooping cough, demonstrating a low rate
of other non-pertussis Bordetella species in our surveilled area.
KEYWORDS B. holmesii, B. parapertussis, Bordetella pertussis, real-time PCR, whooping
cough
Pertussis is a vaccine-preventable acute respiratory disease primarily caused byBordetella pertussis (1). Infants younger than 6 months are at higher risk to suffer
from severe illness, hospitalization, and even fatal outcome (2, 3). Other, less prevalent
Bordetella species, such as Bordetella parapertussis, Bordetella holmesii, and Bordetella
bronchiseptica, can also produce pertussis-like illness.
In the last years and despite extensive vaccination programs, the resurgence of
whooping cough has been documented worldwide. One possible explanation could be
the replacement of B. pertussis by other Bordetella species (4, 5). This fact highlights the
need of using precise diagnosis methods capable of identifying the etiological agent of
Citation Valero-Rello A, Henares D, Acosta L,
Jane M, Jordan I, Godoy P, Muñoz-Almagro C.
2019. Validation and implementation of a
diagnostic algorithm for DNA detection of
Bordetella pertussis, B. parapertussis, and B.
holmesii in a pediatric referral hospital in
Barcelona, Spain. J Clin Microbiol 57:e01231-18.
https://doi.org/10.1128/JCM.01231-18.
Editor Daniel J. Diekema, University of Iowa
College of Medicine
Copyright © 2019 Valero-Rello et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Carmen Muñoz-
Almagro, cma@sjdhospitalbarcelona.org.
A.V.-R. and D.H. contributed equally to this
work.
Received 30 July 2018
Returned for modiﬁcation 5 September
2018
Accepted 24 October 2018
Accepted manuscript posted online 7
November 2018
Published
BACTERIOLOGY
crossm
January 2019 Volume 57 Issue 1 e01231-18 jcm.asm.org 1Journal of Clinical Microbiology
2 January 2019
 o
n
 February 11, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
the disease. An accurate identiﬁcation at the species level is not only important from a
clinical point of view to select the most appropriate antibiotic treatment, but also for
health public purposes, since misdiagnosis of Bordetella species can lead to an incorrect
assessment of pertussis vaccine effectiveness (6).
For this purpose, a number of microbiological techniques are readily available, such
as culture, serology, and nucleic acid ampliﬁcation tests (NAATs) (7). Although culture
remains the gold standard, it has low sensitivity (8, 9). Serology is not an appropriate
method to diagnose pertussis in pediatric populations, since it provides results that are
difﬁcult to interpret in immunized individuals and requires measuring antibody titers in
the acute and convalescent phases of the disease, thus delaying time to result (10).
Rapid, sensitive, and speciﬁc NAATs are being increasingly implemented to overcome
the limitations of culture and serology (9, 11).
NAATs targeting IS481, at high copy number in the genome of B. pertussis, and
IS1001 for B. parapertussis are commonly used (12, 13). However, both targets are also
present in B. holmesii and some B. bronchiseptica strains (14). Several algorithms
combine nonspeciﬁc targets (IS481, IS1001 or IS1002) and may include one or up to two
speciﬁc targets for B. pertussis and B. holmesii (see Table S1). To our knowledge, only
two published methods have reported the use of speciﬁc targets for the three most
relevant Bordetella species (15, 16).
The present study aimed to adapt, optimize, and validate a diagnostic algorithm for
the rapid detection and identiﬁcation of B. pertussis, B. parapertussis, and B. holmesii. In
addition, we sought to assess the disease burden caused by these species in our region
by implementing the algorithm in pediatric patients suspected of pertussis.
(This work was presented in part at the 27th European Congress of Clinical Micro-
biology and Infectious Diseases, Vienna, Austria, 2017 [17].)
MATERIALS AND METHODS
Study design and setting. Nasopharyngeal aspirates (NPAs) were prospectively collected from
children and adolescents 18 years with clinical suspicion of whooping cough (according to CDC
criteria), that were attended in Hospital Sant Joan de Deu (HSJD) between May 2016 and April 2017. This
is a pediatric referral hospital that provides medical care services to more than 300,000 children in
Catalonia (Spain). Information on age and sex variables of the patients was recorded for epidemiological
purposes.
Sample collection and DNA extraction. Nasopharyngeal aspirates were processed according to the
protocol established at the clinical laboratory of the study site (18). Specimens showing poor quality
(rnase P  35 cycle thresholds [CT]) or weak IS481 positivity (40  CT  35) were subjected to additional
DNA extraction using NucliSENS easyMag (bioMérieux, France), from an initial volume of 200 l eluted
into 25 l.
qPCR reference method. The standardized laboratory method of Hospital Sant Joan de Déu (HSJD)
consisted of a duplex quantitative PCR (qPCR) that included hydrolysis probes (Roche Diagnostics GmbH,
Germany) targeting IS481 and the human rnase P gene as a positive internal control for testing sample
quality, as described in Brotons et al. (19) (Table 1). Delta Rn (dRn) CT values were manually set at 0.2 for
both targets.
Samples yielding an IS481 CT of 35 were considered probable B. pertussis isolates, inferred from the
high copy numbers of such targets in this species (estimated in 50 to 200) (20). Samples with a CT value
of 35 to 40 were reported as Bordetella spp., and as negative if CT was 40.
New multiplex qPCR and diagnostic algorithm. Previously published protocols for diagnosis of
whooping cough were reviewed for designing the proposed algorithm (see Table S1). The method by
Tatti et al. (15) was selected as the most complete and accurate basis for designing the new diagnostic
algorithm, in relation to the number of species covered and the use of the human rnase P gene as the
positive control (although not multiplexed). Its conﬁrmatory target for B. pertussis, ptxS1, however, has
been reported as cross-reactive with some strains of B. bronchiseptica (8, 21), so it was replaced by ptxA-Pr
(11). The ﬁnal design of the algorithm included three sequential qPCR assays for the speciﬁc identiﬁcation
of B. pertussis, B. parapertussis, and B. holmesii. The ﬁrst triplex qPCR included the targets IS481, pIS1001
(B. parapertussis-speciﬁc) (13, 15), and the human rnase P (Table 1). If IS481 was positive, two conﬁrmatory
singleplex qPCRs were performed, ptxA-Pr for B. pertussis identiﬁcation (21) and hIS1001 for B. holmesii
(Table 2) (22).
Composition of the qPCR reactions only varied from the reference method in the concentrations and
sequences of oligonucleotides, probes, and the reagents used for rnase P detection (Table 1). The ptxA-Pr
probe was adapted by TIB-Molbiol (Berlin, Germany) to universal ampliﬁcation conditions. dRn CT values
were set at 0.2 for 6-carboxyﬂuorescein (6-FAM) or Yakima Yellow (YAK) probes and at 0.1 for cyanine 3
(Cy3).
Analytical validation. Bacterial strains used were B. pertussis CECT 7974, B. parapertussis ATCC 15311,
and B. holmesii ATCC 51541. DNA standards were prepared from bacterial suspensions in phosphate-
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buffered saline solution (PBS). DNA was extracted using NucliSENS easyMag, and concentrations were
quantiﬁed with the UV-visible (UV-Vis) spectrophotometer Q500 (Quawell, USA). Genome equivalents
(GE) of standards were estimated assuming the molecular size of B. pertussis Tohama I (Genbank
accession number BX470248; 4,086,190 bp), B. parapertussis Bpp5 (Genbank accession number
HE965803; 4,800,120 bp), and B. holmesii ATCC 51541 (Genbank accession number CP007494;
3,699,670 bp).
DNA standards were freshly prepared, by 10-fold dilutions ranging from 106 to 10° GE/ml of sample
(104 to 102 GE/reaction and 105 to 101 fg DNA/reaction). Linear range and intra-assay variability were
estimated by testing each dilution in triplicate on the same day, and consensus curves were used for
calculating the efﬁciencies. Interassay variability was estimated with two additional replicates on
successive days. Precision was acceptable if the mean coefﬁcients of variation (CV) were 3% and 5%
for intra-assay and interassay, respectively.
Analytical speciﬁcity was tested on a panel of 11 bacterial species, including Enterococcus faecalis,
Escherichia coli, Haemophilus inﬂuenzae, Kingella kingae, Moraxella catarrhalis, Neisseria meningitidis,
Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus mitis clinical
isolates, and the Streptococcus pneumoniae R6.
In addition, a reference panel with clinical samples previously processed by the reference method
was also tested by the new triplex qPCR. The purpose of this validation was to compare the performance
of the two techniques targeting IS481 (the gene shared by the two methods) in nasopharyngeal matrices.
NPAs were collected between December 2015 and April 2016 from children 1 year old with suspected
pertussis. All IS481-positive samples by the reference duplex qPCR (n  22), in addition to 22 negative
samples gathered during this period, were subsequently analyzed by the proposed algorithm. Samples
were stored frozen at 80°C between both analyses.
Statistical analysis. Equations for the multiplex and singleplex qPCRs were calculated by plotting
log10-transformed GE versus CT values. Lower limits of detection (LLOD) were estimated using probit
TABLE 1 List of oligonucleotides and probes used in the multiplex and conﬁrmatory qPCRs
Target Named Sequencesc Final concn (nM) Reference or source
IS481 IS481-Ref Fwd TCCGAACCGGATTTGAGAAAC 900 19
IS481-Ref Rev GTCGACGTAGGAAGGTCAATCG 900
IS481-Ref Probe 6-FAM-CGCCAACCCCCCAGTTCACTCA-TAMRA 300
IS481 Fwd CAAGGCCGAACGCTTCAT 770 15
IS481 Rev GAGTTCTGGTAGGTGTGAGCGTAA 770
IS481 Probea 6-FAM-CAGTCGGCCTTGCGTGAGTGGG-BHQ1 260
rnase P rnase P Fwd CCAAGTGTGAGGGCTGAAAAG 150 15
rnase P Rev TGTTGTGGCTGATGAACTATAAAAGG 150
rnase P Probe YAK-CCCCAGTCTCTGTCAGCACTCCCTTC-BHQ1 250
IS1001 pIS1001 Fwd TCGAACGCGTGGAATGG 600 15
pIS1001 Rev GGCCGTTGGCTTCAAATAGA 600
pIS1001 Probeb Cy3-AGACCCAGGGCGCACGCTGTC-BHQ2 200
hIS1001 Fwd GGCGACAGCGAGACAGAATC 900 15
hIS1001 Rev GCCGCCTTGGCTCACTT 900
hIS1001 Probeb Cy3-CGTGCAGATAGGCTTTTAGCTTGAGCGC-BHQ2 300
ptxA-Pr ptxA-Pr Fwd CGCCAAGCTGAAGTAGCA 900 11
ptxA-Pr Rev AAGGAGCGTTCATGCCG 900
ptxA-Pr Probe 6-FAM-AGAATCGAGGGTTTTGTACGACGAATC-BBQ 300 This study
aOriginal ﬂuorophore was modiﬁed for multiplexing.
bOriginal ﬂuorophore and quencher were modiﬁed for multiplexing.
cFluorophores and quenchers of hydrolysis probes are underlined. 6-FAM, 6-carboxyﬂuorescein; TAMRA, 6-carboxytetramethylrhodamine; BBQ, BlackBerry quencher;
Cy3, cyanine 3; BHQ1, black hole quencher 1; BHQ2, black hole quencher 2; YAK, Yakima Yellow.
dRef, reference; Fwd, forward; Rev, reverse.
TABLE 2 Diagnostic algorithm used for the DNA detection and identiﬁcation of Bordetella
species
Species
qPCR result for
Multiplexa
Singleplex ptxA-Pr Singleplex hIS1001IS481 pIS1001
B. pertussis    
B. parapertussis    
B. holmesii    
Bordetella spp.    
arnase P was used as the positive control. , positive; , negative.
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regression analysis at 95% probability (see Table S2). Diagnostic sensitivity and speciﬁcity values were
calculated as reported elsewhere (23).
Continuous variables were described as mean (standard deviation [SD]) or median values (interquar-
tile range [IQR]). Parametric and nonparametric analyses were performed using a t test and the
Mann-Whitney U test, respectively. Categorical data were analyzed by 2 or Fisher’s exact test. Conﬁ-
dence intervals (CI) were set at 95% and signiﬁcance at a two-sided P value of 0.05. All statistical
analyses were performed with SPSS v.22 software (IBM Corp., USA), except for diagnostic sensitivity and
speciﬁcity values, which were calculated with MedCalc Statistical Software v.17.6 (MedCalc Software
Bvba, Belgium).
RESULTS
Analytical validation. Linear ranges obtained spanned from 106 to 101 GE/ml of
sample (r2  0.99). Efﬁciencies ranged from 86.0% to 96.9% (Table 3). LLOD for IS481
were 4.4 and 60.3 GE/ml of sample for B. pertussis and B. holmesii, respectively. Target
pIS1001 showed a LLOD of 13.9 GE/ml of sample, and singleplex reactions hIS1001 and
ptxA-Pr showed LLOD of 27.3 and 777.9 GE/ml of sample, respectively (Table 3 and
Table S2).
Precision estimates (CV) were 3% for all reactions, with 0.32% to 0.94% and 0.58%
to 1.75% values for intra-assay and interassay, respectively (Table 3). Results of the
speciﬁcity panel showed the four Bordetella targets to be genus speciﬁc, and the
conﬁrmatory targets pIS1001, ptxA-Pr, and hIS1001 were species speciﬁc.
The triplex qPCR correctly diagnosed all positive and negative samples of the
reference panel of clinical samples. Sensitivity and speciﬁcity values for IS481 were both
100% (95% CI, 84.6 to 100.0% and 83.2 to 100.0%, respectively). Mean CT for IS481 in the
reference and multiplex reactions were similar despite a freeze-thaw cycle between
tests, with a mean difference between paired samples of 0.94 CT (95% CI,0.40 to 2.78,
P value 0.159).
Burden of disease caused by B. pertussis, B. parapertussis, and B. holmesii.
During the study period, 578 NPAs were collected, from which 9 were excluded, as they
were either processed by a different technique (n  2), invalid samples (n  1), or did
not meet age inclusion criteria (n  6). In addition, 3 samples showed poor quality
(rnase P 35 CT) and were also disregarded. A total of 566 samples was ﬁnally included
in the study. Of them, 484 (85.5%) were negative for the targets IS481 or pIS1001.
Eighty-two samples (14.5%) were Bordetella positive by either IS481 (n  81, 98.8%) or
pIS1001 (n  1, 1.2%). The ptxA-Pr qPCR conﬁrmed B. pertussis infection in 63 samples
(76.8% of positives), and hIS1001 identiﬁed B. holmesii in ﬁve samples (6.1% of posi-
tives), one of them also coinfected with B. pertussis. The remaining 13 positive samples
(15.9%) could not be identiﬁed at the species level and were reported as Bordetella sp.
infection (CT values  30.65 to 38.17).
A seasonal distribution of positive samples was observed, showing a higher inci-
dence during warmer months (P value 0.001) (Fig. 1), 62.2% of them identiﬁed within
TABLE 3 New qPCR performances for each target and Bordetella species
qPCR type Target Bacteria
Target copy
no.b
Curvea Precision (CV %)
Linear rangec Sloped Intercept
Efﬁciency
(%) r2 LLOD
Intra-
assay Interassay
Multiplex IS481 B. pertussis 50 to 200 1.0  106 to 1.0  101 –3.58 40.55 90.3 0.999 4.4  100 0.48 0.69
B. holmesii 8 to 10 0.8  106 to 0.8  102 –3.71 44.36 86.0 0.999 6.0  101 0.63 1.75
pIS1001 B. parapertussis 20 2.2  106 to 2.2  101 –3.40 42.49 96.9 0.999 1.4  101 0.32 0.58
Singleplex ptxA-Pr B. pertussis 1 1.0  106 to 1.0  103 –3.51 49.01 92.8 1.000 7.8  102 0.94 1.35
Singleplex hIS1001 B. holmesii 3 to 5 0.6  106 to 0.6  102 –3.50 43.72 92.9 0.998 2.7  101 0.67 0.81
aPlotting CT versus log10 genome equivalents (GE) per ml of sample.
bNumber of copies present in the genomes of the different Bordetella species (10).
cGenome equivalents of the speciﬁed bacteria per ml of sample. The DNA concentration range for each Bordetella species is as follows: B. pertussis, 0.9  105 to 0.9 
101 fg/reaction (2.0  104 to 2.0  102 GE/reaction); B. parapertussis, 2.3  105 to 2.3  101 fg/reaction (4.4  104 to 4.4  102 GE/reaction); B. holmesii, 1.7 
105 to 1.7·101 fg/reaction (1.6  104 to 1.6  102 GE/reaction) and 5.3  105 to 5.3  101 fg/reaction (1.3  104 to 1.3  102 GE/reaction) for multiplex and
hIS1001, respectively.
dThe symbol () indicates negative values. LLOD, lower limit of detection; CV, coefﬁcient of variation.
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May to July (n  51). B. pertussis was the most frequently detected species, while B.
holmesii and B. parapertussis only circulated during the seasonal peak.
The median age of patients was 1.3 years (IQR, 0.24 to 5.85), and ages ranged from
7 days to 17.5 years. The distribution of B. pertussis was homogeneous across age
groups, whereas B. holmesii was only detected in ﬁve children aged between 4.6 and
9.9 years, and B. parapertussis was only detected in an infant that was two months old
(Fig. 2).
A remarkable difference in the positive rate was observed by age, with the infants
younger than 1 year group showing the lowest positivity rate (7.2%). This rate increased
with the age of patients (Fig. 2).
No differences in positivity rates were observed by gender, with proportions of
14.8% and 14.2% in males and females, respectively (P value 0.857). In contrast, B.
holmesii seemed to show a differential distribution, being only found in females (n 
5, P value 0.06). B. parapertussis was only detected in a specimen taken from a male
patient.
DISCUSSION
The present study proposed a rapid and easy-to-use protocol based on three qPCR
assays for speciﬁc DNA detection of B. pertussis, B. holmesii, and B. parapertussis. The
multicopy targets IS481, pIS1001, and hIS1001 were shown to be very sensitive, with
FIG 1 Seasonal distribution of microbiologically conﬁrmed whooping cough cases by etiological agent
(n  566), includes one coinfection of B. holmesii and B. pertussis (*).
FIG 2 Age distribution of microbiologically conﬁrmed cases and proportion of Bordetella species (n 
566). Includes one coinfection of B. holmesii and B. pertussis (*).
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LLOD values lower than 70 GE/ml of sample. The single-copy target ptxA-Pr had
moderate but acceptable sensitivity, being able to detect 103 GE/ml of sample. qPCR
efﬁciencies were above 90.0% for all targets except for hIS1001 (86%), all of them within
the acceptability limits for qualitative methods (80.0% to 120.0%) (23). This simple and
rapid multiplexed algorithm allowed the speciﬁc identiﬁcation of the three Bordetella
spp. in less than ﬁve hours.
The validated algorithm was implemented during 12 months at the study site. The
most predominant species was B. pertussis, followed by B. holmesii and B. parapertussis.
To date, there are few published European studies investigating the occurrence of
other non-pertussis Bordetella infections. Retrospective studies performed in four Euro-
pean countries between 1992 and 2012 identiﬁed B. pertussis and B. parapertussis in
82.6 to 97.0% and 0.0 to 17.4% of the positive samples, respectively (5, 24–26). None of
these investigations reported B. holmesii infections. However, two recent retrospective
studies from 2013 to 2016 detected B. holmesii in 1.1 to 4.1% of positive samples and
B. parapertussis in 0.3 to 8.2% of positive samples (27, 28). In addition, a study in France
described a very high prevalence, up to 20%, of B. holmesii in adolescents and adults
with pertussis-like symptoms (29). Our ﬁndings, in agreement with Mir-Cros et al. (28),
conﬁrm that B. holmesii is currently circulating in our region, and they could denote its
increase as a causative agent of pertussis-like disease.
The incidence of pertussis in Spain has increased in all age groups despite the high
levels of vaccination coverage (2). In our study, B. pertussis was shown to be evenly
distributed among all ages, while B. holmesiiwas only detected in children4 years old.
This result is concordant with the higher prevalence of B. holmesii in symptomatic
adolescents and adults that was previously reported in several studies (16, 29, 30).
A seasonal distribution of B. pertussis was observed, with higher occurrence in spring
and summer, in line with the epidemiological trends of pertussis in Spain and Europe
(31, 32). Although data of B. parapertussis and B. holmesii incidence rates presented in
this study is limited, it appears to agree with literature suggesting cocirculation with B.
pertussis, also supported by a remarkable number of B. pertussis-B. holmesii coinfections
reported (16, 33, 34).
Bordetella infections were equally frequent in both sexes, as described by others
(31). Interestingly, B. holmesii infection was only detected in females, although the low
number of cases registered does not allow us to reach further conclusions on this
potential association.
One study limitation was the lack of identiﬁcation to species level in 15.9% of
IS481-positive samples. Those Bordetella spp. likely corresponded to B. pertussis, in
which ptxA-Pr qPCR results were negative due to low bacterial load or, less probably but
possibly, to B. bronchiseptica strains for which no speciﬁc gene was investigated.
In conclusion, the new algorithm allowed improvement of accuracy of microbiolog-
ical diagnosis of whooping cough at the study site by enhancing speciﬁcity while
maintaining high sensitivity levels. In addition, we assessed the incidence of Bordetella
spp. among the pediatric population of the geographical region of Catalonia during the
algorithm implementation period. According to our data, the circulation of non-
pertussis Bordetella species in this region seems to be minor and associated with
seasonal increase of B. pertussis. Despite not representing a signiﬁcant contribution to
pertussis disease burden, it is essential to monitor the epidemiological patterns of these
species to conduct an appropriate surveillance of the disease in our region. Neverthe-
less, our local data may not necessarily reﬂect the epidemiological status of Bordetella
species in other areas, since differences in the species circulation can be highly
inﬂuenced according to geographical and time variations (35). Therefore, local evalu-
ations of diagnostic algorithms based on species-speciﬁc primers should carefully be
undertaken before their implementation in any particular region.
Ethical considerations. This study was approved by the ethics committee of HSJD,
in conformity with the Helsinki Declaration of 1975 (revised in 2000); the Spanish
Organic Law 15/1999, on December 13th, on data protection; and law 14/2007, on July
Valero-Rello et al. Journal of Clinical Microbiology
January 2019 Volume 57 Issue 1 e01231-18 jcm.asm.org 6
 o
n
 February 11, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
3rd, on biomedical research. For the present study, no informed consent was requested,
as this is a population-based study in which there were no activities that could
compromise laboratory performance, and samples were duly anonymized.
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